FDA Takes Action to Regulate Unreliable Lab Tests, Ensuring Patient Safety

The Food and Drug Administration (FDA) has proposed a rule to regulate laboratory developed tests (LDTs), including those used for cancer diagnosis and prenatal screening, citing concerns about their reliability and potential harm to patients. LDTs are developed and used in a single laboratory and currently do not require FDA review. The proposed rule would require some tests to undergo agency review before being offered to patients. However, opposition from academic medical centers and commercial laboratories argues that FDA regulation would stifle innovation. The FDA's move aims to address a significant gap in the healthcare system, but critics may attempt to block the final rule through legal action.